An observational study in Lung Cancer Stage IV, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational
The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy. The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,558 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 189 across 1,512 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 920 studies on the registry; 529 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive, treatment-naïve, patients with clinical and radiological suspicion of advanced lung cancer referred for the initial diagnosis/staging/molecular profiling.
Exclusion Criteria:
Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
Distribution of histologic subtypes
The investigators will assess the prevalence of histologic subtypes in patients with advanced lung cancer
Time frame: 24 months
Distribution of histologic subtypes according to clinical and radiological characteristics
The investigators will assess the prevalence of different histologic subtypes according to clinical and imaging characteristics
Time frame: 24 months
Molecular profiling
Prevalence of individual molecular markers in patients with advanced non-squamous non-small cell lung cancer histology
Time frame: 24 months
Time to diagnosis
Time lag between onset of symptoms (if any) and invasive testing
Time frame: 24 months
Plan to share: Undecided — The investigators will decide how to share the data at the end of the study upon reasonable request to be addressed to the principal investigator.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS